Exit the B/Yamagata strain in future influenza vaccines. The 2025/2026 campaign will in fact mark the transition to trivalent vaccines, informs the Directorate General of Health in an urgent DGS of January 6.
Not detected since 2020, the B/Yamagata strain no longer poses a threat to public health according to the EMA, which recommended a transition to trivalent vaccines no later than the 2025/2026 season.
If pre-orders from laboratories, open until March 31, will still be made on the old versions, it is indeed trivalent vaccines which will be delivered to pharmacies. “ As all authorizations have not yet been issued, pharmaceutical laboratories will offer a pre-order based on the quadrivalent vaccine […] and the final order will be made on the basis of the trivalent vaccine when the authorizations have been issued », Details the DGS.
Note that in his back-to-school press conference, on Thursday January 9, the president of the FSPF, Philippe Besset, invited colleagues to order 10% additional doses compared to last year.
For the next campaign, the French vaccine portfolio will be made up of vaccines from Sanofi, Seqirus and Viatris laboratories.
Health
